CN101072582B - 作为癌症疫苗佐剂的α胸腺肽 - Google Patents

作为癌症疫苗佐剂的α胸腺肽 Download PDF

Info

Publication number
CN101072582B
CN101072582B CN2005800417998A CN200580041799A CN101072582B CN 101072582 B CN101072582 B CN 101072582B CN 2005800417998 A CN2005800417998 A CN 2005800417998A CN 200580041799 A CN200580041799 A CN 200580041799A CN 101072582 B CN101072582 B CN 101072582B
Authority
CN
China
Prior art keywords
cancer
vaccine
cells
administration
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2005800417998A
Other languages
English (en)
Chinese (zh)
Other versions
CN101072582A (zh
Inventor
古斯塔沃·安东尼奥·莫威格利亚
阿尔佛雷德·R.·鲁道夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saisheng Pharmaceutical International Singapore Ltd
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of CN101072582A publication Critical patent/CN101072582A/zh
Application granted granted Critical
Publication of CN101072582B publication Critical patent/CN101072582B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2005800417998A 2004-12-06 2005-12-06 作为癌症疫苗佐剂的α胸腺肽 Expired - Lifetime CN101072582B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06
US60/633,175 2004-12-06
PCT/US2005/043985 WO2006062917A2 (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Publications (2)

Publication Number Publication Date
CN101072582A CN101072582A (zh) 2007-11-14
CN101072582B true CN101072582B (zh) 2012-06-27

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800417998A Expired - Lifetime CN101072582B (zh) 2004-12-06 2005-12-06 作为癌症疫苗佐剂的α胸腺肽

Country Status (15)

Country Link
US (1) US20100092499A1 (cg-RX-API-DMAC7.html)
EP (1) EP1835931A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008523067A (cg-RX-API-DMAC7.html)
KR (1) KR20070086663A (cg-RX-API-DMAC7.html)
CN (1) CN101072582B (cg-RX-API-DMAC7.html)
AU (1) AU2005314271B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0518571A2 (cg-RX-API-DMAC7.html)
CA (1) CA2588685A1 (cg-RX-API-DMAC7.html)
EA (1) EA015510B1 (cg-RX-API-DMAC7.html)
IL (1) IL183264A (cg-RX-API-DMAC7.html)
MX (1) MX2007006717A (cg-RX-API-DMAC7.html)
NO (1) NO20072705L (cg-RX-API-DMAC7.html)
NZ (1) NZ555571A (cg-RX-API-DMAC7.html)
UA (1) UA90493C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006062917A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009079338A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
CA2826875A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
BR112014017819B1 (pt) 2012-01-20 2024-01-09 Fernando Thomé Kreutz Método de produzir células cancerígenas imunogênicas isoladas
CN104507491A (zh) * 2012-03-08 2015-04-08 赛生制药有限公司 胸腺素α在治疗化脓性鼻窦炎中的应用
MX386613B (es) * 2014-10-21 2025-03-19 Sciclone Pharmaceuticals Int Sg Pte Ltd El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto.
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1367829A (zh) * 1999-06-30 2002-09-04 科里克萨有限公司 用于肺癌治疗和诊断的组合物和方法
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US20030124136A1 (en) * 2001-10-26 2003-07-03 Hadden John W. Immunotherapy for reversing immune suppression
WO2004003174A2 (en) * 2002-06-28 2004-01-08 Sciclone Pharmaceuticals Inc. Method of up-regulating tumor antigen expression using thymalfasin
WO2004087067A2 (en) * 2003-03-28 2004-10-14 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) * 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
PL370453A1 (en) * 2001-10-26 2005-05-30 Rhode Island Hospital Thymosin augmentation of genetic immunization
ES2428358T3 (es) * 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
CN1367829A (zh) * 1999-06-30 2002-09-04 科里克萨有限公司 用于肺癌治疗和诊断的组合物和方法
US20030124136A1 (en) * 2001-10-26 2003-07-03 Hadden John W. Immunotherapy for reversing immune suppression
WO2004003174A2 (en) * 2002-06-28 2004-01-08 Sciclone Pharmaceuticals Inc. Method of up-regulating tumor antigen expression using thymalfasin
WO2004087067A2 (en) * 2003-03-28 2004-10-14 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Eli Gilboa ,Smita K.Nair, H. Kim Lyerly.Immunotherapy of cancer with dendritic-cell-based vaccines.Cancer Immunol Immunother46 2.1998,46(2),82-87.
Eli Gilboa,Smita K.Nair, H. Kim Lyerly.Immunotherapy of cancer with dendritic-cell-based vaccines.Cancer Immunol Immunother46 2.1998,46(2),82-87. *
Pratima Shrivastava ,Sukh Mahendra Singh ,Nisha Singh.Effect of Thymosin Alpha I on the Antitumor Activity ofTumor-Associated Macrophage-Derived Dendritic Cells.Journal of Biotechnology Science11 5.2004,11(5),摘要.
Pratima Shrivastava,Sukh Mahendra Singh,Nisha Singh.Effect of Thymosin Alpha I on the Antitumor Activity ofTumor-Associated Macrophage-Derived Dendritic Cells.Journal of Biotechnology Science11 5.2004,11(5),摘要. *
Ramsey M Dallal and Michael T Lotze.The dendritic cell and human cancer vaccines.Current Opinion in Immunology12 5.2000,12(5),583-588.
Ramsey M Dallal and Michael T Lotze.The dendritic cell and human cancer vaccines.Current Opinion in Immunology12 5.2000,12(5),583-588. *
蔡在龙, 毛积芳.肿瘤疫苗与肿瘤免疫治疗研究进展.实用肿瘤杂志18 6.2003,18(6),第435页右栏第2-3段.
蔡在龙, 毛积芳.肿瘤疫苗与肿瘤免疫治疗研究进展.实用肿瘤杂志18 6.2003,18(6),第435页右栏第2-3段. *

Also Published As

Publication number Publication date
NZ555571A (en) 2009-02-28
AU2005314271B2 (en) 2011-06-16
BRPI0518571A2 (pt) 2008-11-25
IL183264A (en) 2010-12-30
WO2006062917A2 (en) 2006-06-15
JP2008523067A (ja) 2008-07-03
EA015510B1 (ru) 2011-08-30
WO2006062917A3 (en) 2006-11-16
IL183264A0 (en) 2007-09-20
UA90493C2 (ru) 2010-05-11
AU2005314271A1 (en) 2006-06-15
NO20072705L (no) 2007-09-05
US20100092499A1 (en) 2010-04-15
EP1835931A4 (en) 2008-12-17
EA200701166A1 (ru) 2008-02-28
CA2588685A1 (en) 2006-06-15
MX2007006717A (es) 2007-08-06
CN101072582A (zh) 2007-11-14
EP1835931A2 (en) 2007-09-26
KR20070086663A (ko) 2007-08-27

Similar Documents

Publication Publication Date Title
US20220016164A1 (en) Pharmaceutical composition for use in the treatment of pancreatic cancer
US6689355B2 (en) Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
CA2717854C (en) Allogeneic cancer cell-based immunotherapy
US9694059B2 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
CN101511384A (zh) 采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞
WO2015140172A2 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
CN101072582B (zh) 作为癌症疫苗佐剂的α胸腺肽
Fujii et al. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ
US20210353674A1 (en) Pharmaceutical composition for use in the treatment of pancreatic cancer
WO2002053176A2 (en) An autologous anti-cancer vaccine
RU2192274C2 (ru) Иммуногенная композиция на основе tlp
Bristol et al. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4+ and CD8+ T lymphocytes following in vivo adoptive transfer
US20090060946A1 (en) Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
EP4519418A1 (en) Methods for improving t cell efficacy
JP5227028B2 (ja) インターロイキン−２の中和能を有する免疫治療用製剤
Li et al. Anti-tumour and immune enhancing activities of MLAA-22 379–387 on acute myeloid leukemia
CN120682304A (zh) 一种具有肿瘤细胞杀伤活性的多肽
McKechnie et al. Vaccination and malignant disease: Promising therapeutic approach

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Alpha thymosin peptides as cancer vaccine adjuvants

Effective date of registration: 20180628

Granted publication date: 20120627

Pledgee: China Minsheng Banking Corp Hongkong branch

Pledgor: SciClone Pharmaceuticals, Inc.

Registration number: 2018990000502

PE01 Entry into force of the registration of the contract for pledge of patent right
CP01 Change in the name or title of a patent holder

Address after: California, USA

Patentee after: Saisheng Pharmaceutical Co.,Ltd.

Address before: California, USA

Patentee before: SciClone Pharmaceuticals, Inc.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: California, USA

Patentee after: SCICLONE PHARMACEUTICALS, Inc.

Address before: California, USA

Patentee before: Saisheng Pharmaceutical Co.,Ltd.

PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20200925

Granted publication date: 20120627

Pledgee: China Minsheng Banking Corp Hongkong branch

Pledgor: SCICLONE PHARMACEUTICALS, Inc.

Registration number: 2018990000502

PC01 Cancellation of the registration of the contract for pledge of patent right
TR01 Transfer of patent right

Effective date of registration: 20201124

Address after: Greater Cayman, Cayman Islands

Patentee after: Saisheng Pharmaceutical Co.,Ltd.

Address before: California, USA

Patentee before: SCICLONE PHARMACEUTICALS, Inc.

TR01 Transfer of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Alpha thymosin as adjuvant of cancer vaccine

Effective date of registration: 20210119

Granted publication date: 20120627

Pledgee: China Minsheng Banking Corp Hongkong branch

Pledgor: Saisheng Pharmaceutical Co.,Ltd.

Registration number: Y2021990000077

PE01 Entry into force of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Granted publication date: 20120627

Pledgee: China Minsheng Banking Corp Hongkong branch

Pledgor: Saisheng Pharmaceutical Co.,Ltd.

Registration number: Y2021990000077

PC01 Cancellation of the registration of the contract for pledge of patent right
TR01 Transfer of patent right

Effective date of registration: 20240527

Address after: Singapore City

Patentee after: Saisheng Pharmaceutical International (Singapore) Ltd.

Country or region after: Singapore

Address before: Greater Cayman, Cayman Islands

Patentee before: Saisheng Pharmaceutical Co.,Ltd.

Country or region before: Cayman Islands

TR01 Transfer of patent right
CX01 Expiry of patent term

Granted publication date: 20120627